These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11851322)

  • 1. Peptide-based synthetic recombinant vaccines with anti-viral efficacy.
    Arnon R; Tarrab-Hazdai R; Ben-Yedidia T
    Biologicals; 2001; 29(3-4):237-42. PubMed ID: 11851322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
    El Ridi R; Tallima H
    Vaccine; 2009 Jan; 27(5):666-73. PubMed ID: 19056448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of protective and non-protective T cell epitopes in influenza.
    Crowe SR; Miller SC; Woodland DL
    Vaccine; 2006 Jan; 24(4):452-6. PubMed ID: 16140438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.
    Fu TM; Freed DC; Horton MS; Fan J; Citron MP; Joyce JG; Garsky VM; Casimiro DR; Zhao Q; Shiver JW; Liang X
    Virology; 2009 Mar; 385(1):218-26. PubMed ID: 19070878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes.
    Levi R; Aboud-Pirak E; Leclerc C; Lowell GH; Arnon R
    Vaccine; 1995 Oct; 13(14):1353-9. PubMed ID: 8585293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection.
    Levi R; Arnon R
    Vaccine; 1996 Jan; 14(1):85-92. PubMed ID: 8821654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.
    Ernst WA; Kim HJ; Tumpey TM; Jansen AD; Tai W; Cramer DV; Adler-Moore JP; Fujii G
    Vaccine; 2006 Jun; 24(24):5158-68. PubMed ID: 16713037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.